sugardown(R) Reduces Total Glycemic Index Including Fructose by up to 28 Percent and Insulin Levels by up to 18 Percent; Every Subject Had a Reduction Response MANCHESTER, NH--(Marketwired - Jan 20, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) released additional trial results from its Sydney University study that showed consumption of sugardown® tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a reduction response. Specifically, two sugardown® tablets were found to reduce glucose and fructose levels by up to a total of 20 percent and insulin...
↧